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Background—We explored the safety of intravenous thrombolysis (IVT) or intra-arterial treatment (IAT) in patients with 
ischemic stroke on non-vitamin K antagonist oral anticoagulants (NOACs, last intake <48 hours) in comparison with 
patients (1) taking vitamin K antagonists (VKAs) or (2) without previous anticoagulation (no-OAC).
Methods and Results—This is a multicenter cohort pilot study. Primary outcome measures were (1) occurrence of 
intracranial hemorrhage (ICH) in 3 categories: any ICH (ICH
any), symptomatic ICH according to the criteria of the 
European Cooperative Acute Stroke Study II (ECASS-II) (sICHECASS-II) and the National Institute of Neurological 
Disorders and Stroke (NINDS) thrombolysis trial (sICHNINDS); and (2) death (at 3 months). Cohorts were compared by 
using propensity score matching. Our NOAC cohort comprised 78 patients treated with IVT/IAT and the comparison 
groups of 441 VKA patients and 8938 no-OAC patients. The median time from last NOAC intake to IVT/IAT was 13 
hours (interquartile range, 8–22 hours). In VKA patients, median pre-IVT/IAT international normalized ratio was 1.3 
(interquartile range, 1.1–1.6). ICH
any was observed in 18.4% NOAC patients versus 26.8% in VKA patients and 17.4% 
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in no-OAC patients. sICHECASS-II and sICHNINDS occurred in 2.6%/3.9% NOAC patients, in comparison with 6.5%/9.3% 
of VKA patients and 5.0%/7.2% of no-OAC patients, respectively. At 3 months, 23.0% of NOAC patients in comparison 
with 26.9% of VKA patients and 13.9% of no-OAC patients had died. Propensity score matching revealed no statistically 
significant differences.
Conclusions—IVT/IAT in selected patients with ischemic stroke under NOAC treatment has a safety profile similar to both 
IVT/IAT in patients on subtherapeutic VKA treatment or in those without previous anticoagulation. However, further 
prospective studies are needed, including the impact of specific coagulation tests.  (Circulation. 2015;132:1261-1269. 
DOI: 10.1161/CIRCULATIONAHA.115.015484.)
Key Words: anticoagulants ◼ endovascular procedures ◼ intra-arterial treatment ◼ intracranial hemorrhages  
◼ ischemic stroke ◼ non-vitamin K antagonist oral anticoagulants ◼ thrombolytic therapy ◼ vitamin K antagonists
Atrial fibrillation is a major risk factors for ischemic stroke.1 Non-vitamin K antagonist oral anticoagulants 
(NOACs) are at least as effective as vitamin K antagonists 
(VKAs) in preventing ischemic stroke in patients with atrial 
fibrillation (AF), with a better safety profile, especially for 
intracranial bleeding.2–4 NOACs directly target selected play-
ers in the coagulation cascade as the direct thrombin inhibitor 
dabigatran or the factor Xa inhibitors apixaban, rivaroxaban, 
and edoxaban.2,5 Therefore, onset of the anticoagulatory effect 
of NOACs is quick (peak levels between 2 and 5 hours after 
intake). Anticoagulative effects of NOACs last only for sev-
eral hours to a few days, whereas treatment with VKA results 
in a slow-onset and sustained, long-lasting inhibition of the 
coagulation cascade.6
Clinical Perspective on p 1269
One percent to 2% of all individuals have AF, a proportion 
that will increase as populations age and diagnostic proce-
dures improve. Despite the best medical treatment with VKA 
or NOAC, 1.11% to 3.24% of patients with AF will have an 
ischemic stroke annually.2 Furthermore, patients taking VKAs 
or NOACs for reasons other than AF can develop a stroke. 
Many of these patients will be evaluated at emergency depart-
ments for eligibility for acute recanalization therapies. For 
patients with ischemic stroke despite VKA, there are both 
guidelines7 and registry-based observational data8,9 indicating 
that the use of intravenous thrombolysis (IVT) or intra-arterial 
treatment (IAT) can be safe under certain conditions.
However, it remains uncertain how patients with ischemic 
stroke while taking NOACs should be treated. Current guide-
lines consider IVT contraindicated and mention the cautious 
use of IAT.7 Withholding acute recanalization therapies from 
all patients with acute stroke under NOAC treatment would 
deny an effective treatment to a substantial number of patients 
with stroke.
Theoretical approaches to guide the use of IVT or IAT in 
patients with stroke taking NOACs have been published.10–13 
Furthermore, a few case reports on the use of IVT in patients 
taking dabigatran,14–18 rivaroxaban,19–22 or apixaban,23 or IAT 
while taking dabigatran24 reported favorable clinical out-
comes. Conversely, 1 patient with ischemic stroke under 
dabigatran treatment had a fatal intracranial hemorrhage 
(ICH) associated with IVT.25 Thus, currently, there is a lack 
of systematic outcome and safety data in patients with isch-
emic stroke under NOAC treatment at the time of IVT or IAT. 
Standardized data in large cohorts including any comparison 
group are not available. We therefore orchestrated a multi-
center pilot project to investigate the safety of IVT and IAT for 
acute ischemic stroke in patients taking NOACs. Findings in 
NOAC patients were compared with (1) patients taking VKA 
and (2) patients without anticoagulation (no-OAC) before 
IVT/IAT in an observational cohort study.
Material and Methods
Study Design and Study Population
As a joint initiative of 25 stroke centers (see online-only Data 
Supplement for study group), we performed an observational collab-
orative cohort study to investigate: (1) the incidence of ICHs; and (2) 
functional outcome of patients with ischemic stroke occurring while 
taking NOACs who were treated with IVT or IAT or both (ie, bridg-
ing). IAT included intra-arterial thrombolysis, mechanical revascu-
larization, or both. We introduced 2 comparison groups: first, patients 
with stroke who underwent IVT and IAT while taking VKA, and, 
second, patients without anticoagulation at the time of IVT/IAT.
All participating centers applied IVT/IAT according to well-
established criteria and guidelines,7,26 with the exception that, in 
selected patients, NOAC treatment was not considered an absolute 
exclusion criterion.
Each center reported on all NOAC patients treated with IVT/IAT 
during the period for which they had prospectively recorded data 
on consecutive patients treated with IVT/IAT in local registries or 
lists since approval of the first NOAC for stroke prevention in AF in 
their country up to December 31, 2014. Selected centers also pro-
vided information on all patients with stroke treated with IVT/IAT (1) 
while taking VKAs and (2) those without previous anticoagulation 
(no-OAC) based on local registries. For each contributing center, the 
number of patients, recruitment periods, and type of data source are 
summarized in Table I in the online-only Data Supplement.
Data Collection
Data for all patients were collected using a standardized form with 
predefined variables, as done in previous research.27–29 Local inves-
tigators completed the forms systematically using data from (1) pro-
spectively ascertained in-hospital thrombolysis or stroke registries or 
(2) from patients’ records and charts in case patients were identified 
by local patient lists about consecutive IVT/IAT. Completed forms 
from all centers were sent to the coordinating center in Basel, where 
analyses of pooled data were performed.
Baseline Data
The following variables were used: age, sex, stroke severity as 
assessed by the National Institutes of Health Stroke Scale (NIHSS) 
score before IVT/IAT and at 24 hours, occlusion of main intracra-
nial arteries (assessed by computed tomography angiography or 
magnetic resonance angiography), blood pressure, time-to-treat-
ment, etiology according to the Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) criteria, and the following risk factors applying 
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predefined criteria27: hypertension, diabetes mellitus, hypercholester-
olemia, coronary artery disease, history of previous ischemic stroke. 
Previous use of antiplatelets, antihypertensive drugs, and statins was 
assessed.30 Laboratory measures before IVT/IAT included blood glu-
cose levels, creatinine,27 platelet count, international normalized ratio 
(INR), activated partial thromboplastin time (aPTT), and calibrated 
anti–factor Xa assays for rivaroxaban, if available. Current use of 
VKAs or NOACs was recorded. In patients taking NOACs, agent and 
daily dosage, reason for use, last intake (in hours before IVT/IAT), 
and categorized reason for using IVT/IAT treatment were recorded. 
Functional 3-month outcome was assessed by outpatient visits or 
telephone interviews by using the modified Rankin Scale (mRS).
Outcome Measures
Primary outcome measures were the occurrence of ICH in 3 cate-
gories, or death within 3 months (ie, mRS of 6, denoted as mRS6). 
ICH included: (1) any ICH on follow-up imaging including hemor-
rhagic transformation (ICH
any); (2) symptomatic ICH (sICH) accord-
ing to the criteria of the European Cooperative Acute Stroke Study II 
(ECASS-II) trial31 (sICHECASS-II); and (3) sICH based on the criteria of 
the National Institute of Neurological Disorders and Stroke (NINDS) 
thrombolysis trial32 (sICHNINDS).
Secondary outcome measures were: (1) NIHSS at 24 hours; 
(2) major neurological improvement, defined as an improvement in 
NIHSS score of 8 points at 24 hours in comparison with the initial 
NIHSS (or an NIHSS score of 0 at 24 hours) as defined in previous 
research33; and (3) favorable 3-month outcome (ie, mRS of 0, 1, or 2, 
denoted as mRS0-2).
Statistical Analyses
We used a bootstrapping procedure34 that combined propensity score 
matching35 with multiple imputation.36 Because of the heterogeneous 
sample sizes between groups, we used triple group (TriMatch37) 
propensity score matching (PSM38) to balance characteristics of 
patients according to baseline covariates. Propensity scores were esti-
mated from a logistic model and matched against a caliper of 0.2539. 
Variables likely to affect outcome or complications were chosen based 
on previous studies.27–30 PSM predictors were age, sex, time-to-treat-
ment, admission NIHSS, systolic and diastolic blood pressure, blood 
glucose level, creatinine and prior medication with statins, antihyper-
tensive agents, or antiplatelets, as well, and the presence of diabetes 
mellitus, hypertension, hypercholesterolemia, coronary artery disease, 
atrial fibrillation, and history of previous ischemic stroke.
Statistical analysis proceeded in 3 steps. First, missing data among 
the set of PSM predictors were completed by single imputation. 
Across all variables, 6.2% of data were missing (interquartile range 
[IQR], 0.6%–9.4%). Min/max of data missing for PSM were <0.1% 
[age]/0.3% [NIHSS on admission] and 15.9% [creatinine on admis-
sion]. Note that outcome variables were not imputed, but patients with 
missing values were dropped from analysis. Second, propensity scores 
were estimated and patients in the NOAC, VKA, and no-OAC groups 
were matched based on their propensity scores. Third, statistical analy-
ses were performed on the matched sample and test statistics retained. 
Overall differences in NIHSS at 24 hours were analyzed with univari-
ate analysis of variance with treatment group as the between-subjects 
factor. Pairwise comparisons between treatment groups were computed 
as a priori contrasts. Overall differences in the proportion of patients 
with ICH
any, major neurological improvement, mRS0-2, and mRS6 were 
tested with χ² tests. Pairwise differences between treatment groups 
for ICH
any, major neurological improvement, mRS0-2, and mRS6 were 
assessed with 2-sample binomial tests. Pairwise differences for sICH-
NINDS and sICHECASS-II were tested by using the Fisher exact test. Overall 
differences for sICHECASS-II and sICHNINDS could not be evaluated owing 
to very low incident rates in the NOAC group. Only pairwise Fisher 
exact tests were computed. Odds ratios and their 95% confidence inter-
vals are provided for all instances of statistical significance. This proce-
dure was repeated 50 000 times to gain a reliable bootstrap estimation 
of the empirical distribution of test statistics and P values.
Statistical analyses were performed by using R for Windows, 
version 3.1.2. All tests were 2-tailed, and statistical significance was 
determined at the α-level of 0.05. All pairwise tests used the Šidák 
correction for multiple comparisons,40 yielding α′=0.003.
Subgroup Analyses
First, patients treated with IVT only (ie, excluding those with IAT 
only) were analyzed by comparing all groups. Second, in NOAC 
patients, all patients with IVT/IAT decisions based on the findings 
of the calibrated anti–factor Xa assays were descriptively analyzed. 
Third, we applied a post hoc comparison of NOAC patients with 
VKA patients stratified to the INR in 2 strata: VKA with INR >1.7 
and with INR ≤1.7. For all subgroup analysis, we performed descrip-
tive analyses only, owing to the small numbers.
Ethics
The study was approved by the ethics committee in Basel, Switzerland. 
The requirement for additional local ethical approval differed among 
participating centers and was acquired as necessary.
Results
Study Population
Our patient cohort included 9457 patients with acute ischemic 
stroke treated with IVT or IAT. The NOAC cohort comprised 
78 patients (apixaban n=2, dabigatran n=29, and rivaroxaban 
n=47). IVT was used in 51 NOAC patients, including 6 who 
received IVT followed by IAT. IAT only was used in 27 NOAC 
patients; 25 of these 27 patients underwent purely mechani-
cal thrombectomy. The comparison groups comprised (1) 441 
VKA (phenprocoumon or acenocoumarol in all centers except 
Helsinki/Finland: warfarin) patients and (2) 8938 patients that 
were not on anticoagulation when they received IVT or IAT 
(no-OAC; Table I in the online-only Data Supplement).
Baseline Characteristics
There were significant differences in baseline characteristics 
between all cohorts. Baseline characteristics and the recanali-
zation therapies applied are displayed in Table 1 (before PSM) 
and Table 2 (after PSM).
Last Intake, Coagulation Parameters, and 
Indication for NOAC Treatment
For NOAC patients, the median time between last intake and 
IVT/IAT was 13 hours (IQR, 8–22 hours); it was ≤12 hours 
in 38 patients, 13 to 24 hours in 30 patients, 25 to 48 hours in 
7 patients; and unknown (but within <48 hours) in 3 patients. 
Atrial fibrillation was the indication for NOAC use in 69 of 78 
(88%) patients. Other indications included prevention (n=2) 
and treatment (n=3) of deep vein thrombosis and other/not 
recorded (n=4).
In patients receiving rivaroxaban (n=47), the median INR 
was 1.3 (IQR, 1.1–1.51) and the mean aPTT was 32 (IQR, 
27–35) seconds; in patients receiving dabigatran (n=29), 
median INR was 1.3 (IQR,1.1–1.5) and mean aPTT was 32 
(IQR, 27–35) seconds. The 2 apixaban patients had INRs of 
1.18 and 1.16 and aPTTs of 32 and 33 seconds, respectively.
In the VKA group, the median INR was 1.3 (IQR, 1.1–
1.58). In 308 VKA patients (69.8%), the INR was ≤1.7. In 80 
VKA patients (18.1%), no INR was recorded. Among the 53 
VKA patients (12%) with INR >1.7 (median, 2.0 [IQR, 1.9–
2.35]), 37 were treated with IVT, whereas 16 had IAT (median 
INR, 2.15[IQR, 2.0–2.87]).
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The reported decision to use IVT/IAT in NOAC patients was 
based on the time since last intake >24 hours (n=10), low levels in 
drug-specific coagulation assays (n=23), normal values in routine 
coagulation assays (n=10), or on other/unknown reasons (n=35). 
The latter included patients in which the use of NOAC was not 
known before IVT/AT treatment but discovered thereafter.
Outcome Measures
Outcome measure statistics are displayed in Table 3 (before 
PSM) and Table 4 (after PSM).
Primary Outcome Measures
ICH
any was observed in 14 of 76 (18.4%) NOAC patients in 
comparison with 105 of 394 (26.6%) VKA patients, and 1332 
of 7677 (17.4%) patients in the no-OAC group (P=0.30). 
sICHECASS-II occurred in 2 of 76 (2.6%) NOAC patients in com-
parison with 27 of 415 (6.5%) VKA patients and 417 of 8281 
(5.0%) no-OAC patients (P=0.48). sICHNINDS was reported 
for 3 of 76 (3.9%) NOAC patients, 40 of 432 (9.3%) VKA 
patients, and 616 of 8539 (7.2%) no-OAC patients (P=0.56). 
At 3 months, 17 of 74 (23.0%) NOAC patients had died in 
comparison with 113 of 420 (26.9%) VKA patients and 1172 
of 8414 (13.9%) no-OAC patients (P=0.44).
Secondary Outcome Measures
A favorable 3-month outcome occurred in 30 of 74 (40.5%) 
NOAC patients in comparison with 166 of 420 (39.5%) VKA 
patients and 4736 of 8414 (56.3%) no-OAC patients. Here, we 
find the only significant overall difference of frequencies in 
our data (P=0.037). The pattern of frequencies suggests a more 
favorable 3-month outcome for no-OAC patients than for the 
VKA and the NOAC patients. Pairwise comparisons, however, 
remain insignificant in all cases (all P>0.05). Major neurologi-
cal improvement occurred similarly often in all 3 groups.
Table 1. Baseline Characteristics (Before Matching)
Novel Oral Anticoagulants Vitamin K Antagonists no-OAC Statistics
(n=78) (n=441) (n=8938) P Value
Age, y, median (IQR) 76 (68–81) 77 (68–83) 71 (60–79) < 0.001*
Female sex, n (%) 36 (49.3) 201 (45.6) 3915 (43.9) 0.50†
Time-to-treatment, min, median (IQR) 174.5 (115.5–240) 140 (90–185) 126 (80–175) <0.001*
NIHSS score, median (IQR) 14.5 (7–19) 14 (8–19) 10 (6–16) <0.001*
INR, median (IQR) 1.14 (1.06–1.3) 1.3 (1.1–1.6) 1 (1–1.1) <0.001*
Occlusion of intracranial artery, n (%) 50 (75.8) 174 (68.5) 2070 (46.7) < 0.001†
Systolic blood pressure, mm Hg, mean (IQR) 148 (127.5–164.5) 151.5 (132–170) 154 (139–170) 0.15*
Diastolic blood pressure, mm Hg, mean (IQR) 80 (67–93.5) 83 (73–94) 83 (74–94) 0.18*
Type of acute recanalization therapy‡
  IV thrombolysis only, n (%) 45 (57.7) 354 (84.9) 7788 (93.2)
  IV thrombolysis and IA treatment, n (%) 6 (7.69) 36 (8.63) 521 (6.24)
  IA treatment only, n (%) 27 (34.62) 27 (6.47) 43 (0.51)
Concomitant treatment
  Previous use of statins, n (%) 27 (39.1) 160 (38) 1954 (25.5) <0.001†
  Previous use of antihypertensive drugs, n (%) 61 (87.1) 346 (82.2) 4424 (54.4) <0.001†
  Previous treatment with antiplatelets, n (%) 14 (18.2) 64 (14.8) 3008 (35.8) <0.001†
Risk factors
  Atrial fibrillation, n (%) 68 (87.2) 345 (78.8) 2152 (24.3) <0.001†
  Diabetes mellitus, n (%) 17 (24.3) 98 (22.2) 1500 (16.8) 0.07†
  Hypertension, n (%) 61 (87.1) 349 (79.1) 5627 (63.2) <0.001†
  Hypercholesterolemia, n (%) 32 (49.2) 184 (42.5) 3559 (41.4) 0.45†
  Coronary artery disease, n (%) 24 (34.3) 107 (25.4) 1371 (16.9) <0.001†
  History of stroke, n (%) 18 (25.4) 110 (25.4) 1211 (14) <0.001†
Stroke cause‡
  Cardioembolic, n (%) 64 (85.3) 224 (61.4) 2623 (33.1)
  Large artery atherosclerosis, n (%) 2 (2.7) 97 (26.6) 2003 (25.3)
  Small artery occlusion, n (%) 0 (0) 3 (0.82) 574 (7.25)
  Other, n (%) 1 (1.33) 11 (3.01) 338 (4.27)
  >1 or undetermined, n (%) 8 (10.67) 29 (7.95) 2233 (28.21)
IA indicates intra-arterial; INR, international normalized ratio; IQR, interquartile rate; IV, intravenous; NIHSS, National Institutes of Health Stroke Scale; and no-OAC, 
without previous anticoagulation.
*Kruskal-Wallis test with df=2
†χ² test with df=2
‡No test computed (small sample sizes).
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Subgroup Analyses
IVT Only
IVT only was used in 51 NOAC and 390 VKA patients. ICH
any 
occurred in 8 (15.7%) patients on NOAC and 54 (28.7%) 
patients on VKA. sICHECASS-II and sICHNINDS occurred in 2 
(4.0%) patients on NOAC each, in comparison with 7 (3.6%) 
and 11 (5.7%) patients on VKA.
IVT/IAT and Calibrated Anti–Factor Xa Assays
In 21 patients taking rivaroxaban, the decision to administer 
IVT was based on calibrated anti-factor Xa assays with a mean 
level of 21ng/mL (IQR, 8–23 ng/mL). In all these patients 
anti–factor Xa levels were <100 ng/mL. Each of the 3 patients 
with anti–factor Xa levels of >100ng/mL (range, 146–246 ng/
mL) had IAT only. None of these patients experienced a sICH.
NOAC and VKAINR>1.7 or VKAINR≤ 1.7
Outcome measures for the subgroup analysis comparing 
patients on NOAC and VKAINR>1.7 or VKAINR≤ 1.7 are summa-
rized in Table 5.
Discussion
This observational multicenter pilot study yielded the follow-
ing key findings: first, in selected patients with ischemic stroke 
who are on NOAC treatment (last intake ≤48 hours), IVT/IAT 
was feasible and not associated with an excessive risk of ICH 
in comparison with patients on VKA or without oral antico-
agulation. Second, in comparison with VKA patients, NOAC 
patients had numerically fewer intracranial hemorrhages, 
lower death rates, and a better functional outcome. However, 
none of these differences reached statistical significance.
Overall, our study highlights that, at least in experienced 
stroke centers, IVT/IAT application in carefully selected 
patients with ischemic stroke under NOAC treatment did not 
raise any suggestion of safety concerns.
The percentage of sICHECASS-II (2.6%) or sICHNINDS (3.9%) 
in our NOAC cohort was comparable to sICH rates in a recent 
multicenter observational study (4.7%)41 or in ECASS-3 
(5.3%).42 This finding might not be necessarily reassur-
ing, because the upper limit of the 95%CI (ie, 6.13% for 
Table 2. Baseline Characteristics After Propensity Score Matching
Novel Oral Anticoagulants Vitamin K Antagonists no-OAC
(n=63) (n=339) (n=210)
Age, y, median (IQR) 76 (64–81) 77 (68–83) 75 (67–81)
Female sex, n (%) 28 (45) 158 (46.6) 108 (51.5)
Time-to-treatment, min, median (IQR) 176 (117–242) 141 (93–180) 132 (90–176)
NIHSS score, median (IQR) 15 (7–19) 14 (8–19) 14 (8–19)
INR, median (IQR) 1.14 (1.07–1.3) 1.3 (1.1–1.59) 1.05 (1–1.12)
Occlusion of intracranial artery, n (%) 45 (76.6) 150 (70) 59 (54.5)
Systolic blood pressure, mm Hg, mean (IQR) 148 (128–165) 151 (131–170) 151 (135–168)
Diastolic blood pressure, mm Hg, mean (IQR) 80 (68–93) 83 (73–93) 81 (72–93)
Type of acute recanalization therapy
  IV thrombolysis only, n (%) 34 (53.5) 287 (84.8) 196 (93.2)
  IV thrombolysis and IA treatment, n (%) 4 (6.3) 29 (8.7) 13 (6.1)
  IA treatment only, n (%) 25 (40.2) 22 (6.5) 1 (0.7)
Concomitant treatment
  Previous use of statins, n (%) 25 (40) 112 (34.1) 71 (35.9)
  Previous use of antihypertensive drugs, n (%) 56 (88.9) 275 (82.4) 180 (87.2)
  Previous treatment with antiplatelets, n (%)) 13 (19.9) 49 (14.6) 51 (24.5)
Risk factors
  Atrial fibrillation, n (%) 54 (86) 265 (78.2) 176 (84.1)
  Diabetes mellitus, n (%) 16 (24.7) 68 (20.1) 50 (23.9)
  Hypertension, n (%) 55 (87.5) 269 (79.3) 173 (82.6)
  Hypercholesterolemia, n (%) 31 (52.6) 146 (43) 98 (47.2)
  Coronary artery disease, n (%) 21 (32.6) 80 (24.3) 62 (29.8)
  History of stroke, n (%) 15 (24.1) 61 (18.2) 45 (21.3)
Stroke cause
  Cardioembolic, n (%) 50 (82.1) 171 (59) 105 (53)
  Large artery atherosclerosis, n (%) 2 (3.3) 83 (28.8) 68 (34.1)
  Small artery occlusion, n (%) 0 (0) 2 (0.8) 3 (1.6)
  Other, n (%) 1 (1.7) 10 (3.4) 2 (0.9)
  >1 or undetermined, n (%) 8 (13) 23 (8) 21 (10.4)
IA indicates intra-arterial; INR, international normalized ratio; IA, intra-arterial; IQR, interquartile rate; IV, intravenous; NIHSS, National 
Institutes of Health Stroke Scale; and no-OAC, without previous anticoagulation.
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sICHECASS-II and 8.2%for ICHNINDS, respectively) indicates that 
the sICH risk might still be higher than reported in literature 
for patients without anticoagulation. Based on the observa-
tion that the ICH risk in all categories was numerically lower 
in NOAC than in VKA patients, this scenario seems unlikely, 
taking into account that IVT/IAT in VKA patients has been 
reported safe under certain conditions.8,9 Reasons for the rela-
tive safety of IVT/IAT under NOAC may include the lower 
baseline risk of ICH of NOACs in patients with stroke.3
The decision to use IVT was based on rivaroxaban con-
centration levels in the calibrated anti–factor Xa assay in 22 of 
our patients and 2 recent single cases.19,21 All 24 IVT-treated 
patients had levels of the calibrated anti–factor Xa assay 
<100ng/mL. None had sICH but 1 of 24 had an asymptom-
atic ICH. This threshold, recommended previously based on 
theoretical and pharmacological considerations and data,11 
may indeed serve as a clinically useful tool to select patients. 
However, because of the small sample size, further research 
about the clinical meaning of NOAC-concentration thresholds 
is needed.
Our analysis had the following strengths: (1) We report on 
a multicenter cohort; (2) data ascertainment was undertaken 
systematically and included 2 comparison groups; and (3) 
safety issues, and functional outcome, as well, were addressed.
Table 3. Primary and Secondary Outcome Measures Before Matching
Novel Oral Anticoagulants Vitamin K Antagonists no-OAC Statistics
(n=78) (n=441) (n=8938) p
Primary outcome
  ICH
any 14 of 76 (18.4%) 105 of 394 (26.6%) 1332 of 7677 (17.4%) <0.001
  sICH
ECASS-II 2 of 76 (2.6%) 27 of 415 (6.5%) 417 of 8281 (5.0%) .25*
  sICH
NINDS 3 of 76 (3.9%) 40 of 432 (9.3%) 616 of 8539 (7.2%) .15
  Death at 3 mo (mRS
6) 17 of 74 (23.0%) 113 of 420 (26.9%) 1172 of 8414 (13.9%) <0.001
Secondary outcome
  NIHSS at 24 h, median (IQR)   9 (2–14)    8 (3–16)      5 (2–13) <0.001
  Major neurological 
improvement*
24 of 77 (31.2%) 128 of 405 (31.6%) 1958 of 6834 (28.7%) .40
  Favorable clinical outcome  
at 3 mo (mRS0-2)
30 of 74 (40.5%) 166 of 420 (39.5%) 4736 of 8414 (56.3%) <0.001
ECASS-II indicates European Cooperative Acute Stroke Study II; ICH, intracranial haemorrhage; ICHany, any intracranial hemorrhage; IQR, 
interquartile range; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NINDS, National Institute of Neurological 
Disorders and Stroke; no-OAC, without previous anticoagulation; sICH, symptomatic intracranial hemorrhage sICHECASS-II, any ICH with 
neurological deterioration, as indicated by an NIHSS score that was higher by ≥4 points than the value at baseline or the lowest value in 
the first 7 days, or any hemorrhage leading to death; and sICHNINDS, any ICH on follow-up imaging with any decline in neurological status.
* Major neurological improvement – improvement in NIHSS score of 8 points at 24 h compared to initial NIHSS (or NIHSS score 
of 0 at 24 h)
Table 4. Primary and Secondary Outcome Measures After Propensity Score Matching
Novel Oral Anticoagulants Vitamin K Antagonists no-OAC Statistics
(n=63) (n=339) (n=210) P Value
Primary outcome
  ICH
any 13 of 62 (20.8%) 85 of 300 (28.4%) 44 of 184 (23.8%) 0.30
  sICH
ECASS-II 2 of 62 (3.2%) 21 of 338 (6.1%) 14 of 207 (6.6%) 0.48*
  sICH
NINDS 3 of 62 (4.8%) 30 of 338 (8.9%) 19 of 203 (9.6%) 0.56*
  Death at 3 mo (mRS
6) 16 of 60 (26.1%) 76 of 324 (23.6%) 43 of 204 (20.9%) 0.44
Secondary outcome
  NIHSS at 24 h, median (IQR)   10 (2–15)    8 (3–16)    8 (3–17) 0.45
  Major neurological 
improvement†
20 of 62 (31.4%) 98 of 317 (30.8%) 41 of 154 (26.3%) 0.29
  Favorable clinical outcome 
at 3 mo (mRS
0-2)
23 of 60 (39%) 138 of 324 (42.7%) 88 of 204 (43.2%) 0.03‡
ECASS-II indicates European Cooperative Acute Stroke Study II; ICH, intracranial haemorrhage; ICHany, any intracranial hemorrhage; IQR, interquartile 
range; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NINDS, National Institute of Neurological Disorders and 
Stroke; no-OAC, without previous anticoagulation; sICH, symptomatic intracranial hemorrhage; sICHECASS-II, any ICH with neurological deterioration, as 
indicated by an NIHSS score that was higher by ≥4 points than the value at baseline or the lowest value in the first 7 days, or any hemorrhage leading 
to death; and sICHNINDS, any ICH on follow-up imaging with any decline in neurological status.
*χ² approximation unstable (small group sizes).
†Major neurological improvement – improvement in NIHSS score of 8 points at 24 h compared to initial NIHSS (or NIHSS score of 0 at 24 h).
‡All pairwise comparison: P>0.05.
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Nevertheless, several limitations should be noted: First, 
this is a retrospective study. Second, there was heterogene-
ity between centers with regard to the criteria applied for the 
decision to use or avoid IVT/IAT in individual patients, and 
whether IVT or IAT was preferred. Third, NOAC patients dif-
fered from the VKA and the no-OAC patients in several base-
line characteristics. Despite application of PSM as an effort 
to minimize confounding effects, unmeasured characteristics 
might have differed between these patients and confounded 
our results. Fourth, a comparison group of patients with stroke 
despite NOAC treatment not treated with IVT/IAT was not 
available. Thus, the bleeding risk in patients with ischemic 
stroke taking NOACs treated with IVT/IAT versus those with-
out IVT/IAT could not be studied. Fifth, despite being the 
largest cohort available so far, the total numbers of patients 
taking NOACs or VKAs are still relatively small. Thus, sub-
group analyses were performed descriptively. Accordingly, 
we stress the exploratory character of our study and urge a 
cautious interpretation of our findings.
The safety of IVT in patients on VKA and an INR ≤1.7 
has been established based on large cohorts.8,9 The knowl-
edge about IVT in NOAC patients is limited and based on 
case reports.14–18,20,21,24 Data from animal models showed no 
excessive risk of ICH after IVT in rodents with a prior treat-
ment with rivaroxaban,43,44 dabigatran,45,46 and apixaban44 in 
comparison with VKA. Currently, the use of IVT for acute 
ischemic stroke in patients with a recent (<48 hours) intake 
of a NOAC is regarded off-label.7 A recent survey among US 
vascular neurologists showed a lack of consensus regarding 
the management of patients with ischemic stroke on dabi-
gatran.47 The guidelines of the American Heart Association/
American Stroke Association state that IVT might be consid-
ered “[if] sensitive laboratory tests such as aPTT, INR, platelet 
count, and ECT, TT, or appropriate direct factor Xa activity 
assays are normal, or the patient has not received a dose of 
these agents for >2 days (assuming normal renal metaboliz-
ing function).”7 NOACs have only limited influence on stan-
dard coagulation assays.48 Practical approaches for the use 
of IVT/IAT in patients with stroke taking NOACs have been 
proposed.10,11 A recently developed and prospectively assessed 
approach for patients with stroke despite dabigatran by using 
aPTT and thrombin time reported on 2 patients receiving IVT 
within 8 months of recruitment. Neither had ICH.49
Twenty-seven of our NOAC patients were treated with IAT 
only; 25 of those had pure mechanical thrombectomy. sICH 
was absent in all patients and also in a case report of mechanical 
thrombectomy under NOAC.24 Despite the small numbers, the 
absence of sICH suggests, that in patients with abnormal hemo-
stasis and NOAC treatment, mechanical recanalization strategies 
might be more appropriate. However, it remains to be shown, 
whether sICH rates are indeed lower when NOAC patients with 
acute stroke are treated with mechanical IAT than with IVT. For 
patients with abnormal hemostasis50,51 and treatment with IAT, 
sICH rates were 7.1%50 and 11.4%,51 which were numerically 
higher than those observed in our NOAC cohort treated with IVT.
In conclusion, our data suggest that IVT/IAT treatment 
in patients with an ischemic stroke despite NOAC is feasible 
and probably not associated with an excessive risk for ICH. 
However, this assumption requires that patients (1) are treated 
in experienced stroke centers and (2) are carefully selected 
based on time from last intake of the oral anticoagulant and 
the findings of specific coagulation tests. Nevertheless, our 
observations must be considered with caution before gener-
alizing them to standard practice. More research is needed, 
which should include a systematic assessment of the clinical 
meaning of coagulation tests and drug doses with regard to 
safety and effectiveness measures. We recently set up a pro-
spective multicenter registry to systematically investigate the 
management of patients experiencing an acute ischemic stroke 
or intracranial hemorrhage while taking NOACs (NOACISP-
ACUTE, cinicaltrials.gov: NCT02353585).
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Table 5. Outcome Measures Stratified to VKA With INR Subgroups Versus NOAC Patients
Vitamin K Antagonists Novel Oral Anticoagulants
INR >1.7 INR ≤1.7
(n=135) (n=306) (n=78)
Primary outcome
  ICH
any 36 of 123 (29.27%) 69 of 271 (25.46%) 14 of 76 (18.42%)
  sICH
ECASS-II 13 of 116 (11.21%) 14 of 299 (4.68%) 2 of 76 (2.63%)
  sICH
NINDS 16 of 135 (11.85%) 24 of 297 (8.08%) 3 of 76 (3.95%)
  Death at 3 mo (mRS
6) 38 of 129 (29.46%) 75 of 291 (25.77%) 17 of 74 (22.97%)
Secondary outcome
  NIHSS at 24 h, median (IQR)   9 (3–17)   8 (3–16)   9 (2–14)
  Major neurological improvement 42 of 123 (34.15%) 86 of 282 (30.50%) 24 of 77 (31.17%)
  Favorable clinical 3-mo outcome (mRS
0-2) 57 of 129 (44.19%) 109 of 291 (37.46%) 30 of 74 (40.54%)
ECASS-II indicates European Cooperative Acute Stroke Study II; ICH, intracranial haemorrhage; ICHany, any intracranial hemorrhage; IQR, 
interquartile range; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NINDS, National Institute of Neurological 
Disorders and Stroke; sICH, symptomatic intracranial hemorrhage; sICHECASS-II, any ICH with neurological deterioration, as indicated by an NIHSS 
score that was higher by ≥4 points than the value at baseline or the lowest value in the first 7 days, or any hemorrhage leading to death; and 
sICHNINDS, any ICH on follow-up imaging with any decline in neurological status.
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CLINICAL PERSPECTIvES
Non-vitamin K antagonist oral anticoagulants (NOACs) changed clinical practice and are now frequently used for stroke 
prevention in patients with atrial fibrillation. Despite their efficacy, patients with atrial fibrillation taking NOACs might 
experience an ischemic stroke. Clinical physicians are faced with the dilemma to evaluate patients on NOACs who present 
with ischemic stroke in stroke centers and to balance the risk of bleeding complications against benefits of recanalization 
therapies like intravenous thrombolysis (IVT) and intra-arterial treatment (IAT, including mechanical thrombectomy). This 
multicenter observational pilot study is the first to report on a cohort of patients with a previous recent (within the last 48 
hours) intake of a NOAC treated with IVT/IAT for ischemic stroke and compares bleeding complications and outcome with 
a large data set of patients who were either on Vitamin K antagonists or without anticoagulation before IVT/IAT. In this 
study, in selected patients with ischemic stroke under NOAC treatment, IVT/IAT had a safety profile similar to both IVT/
IAT in patients on subtherapeutic Vitamin K antagonist treatment or in those without previous anticoagulation. The present 
study suggests that IVT/IAT in patients with a previous intake of a NOAC might be safe and that specific clotting tests (eg, 
calibrated anti–factor Xa assays or hemoclot test) might be helpful to guide or support treatment decisions. Nevertheless, 
treatment with IVT/IAT in patients with a previous intake of a NOAC should be based on individual treatment decisions 
balancing the risks and benefits. It should be discussed with patients and next-of-kin. However, more data are needed and 
results from ongoing research studies are warranted (for example, NOACISP-ACUTE, cinicaltrials.gov: NCT02353585).
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SUPPLEMENTAL MATERIAL 
 
Novel oral anticoagulants in stroke patients (NOACISP) Study Group*   
Belgium: R-J Van Hooff and R. Brouns, Department of Neurology, University Hospital, 
Center for Neurosciences (C4N), Brussels; 
France: Y. Béjot and M Giroud, Department of Neurology, University Hospital, Dijon; C. 
Cordonnier, D. Leys, M. Ferrigno and N. Dequatre-Ponchelle, Department of Neurology, 
University Hospital, Lille; G. Turc and J.L. Mas, Department of Neurology, Sainte-Anne 
Hospital, Paris; C. Oppenheim and O. Naggara, Department of Neuroradiology, Sainte-Anne 
Hospital, Paris 
Finland: D. Strbian and T. Tatlisumak, Department of Neurology, University Central 
Hospital, Helsinki;  
Germany: H. Erdur and Ch. Nolte, Department of Neurology and Center for Stroke Research 
Charité, Berlin; A. Grau and F. Palm, Department of Neurology, Municipal Hospital 
Ludwigshafen, W. Pfeilschifter, Department of Neurology, University Hospital, Frankfurt am 
Main; B. Ikenberg and Th. Steiner, Department of Neurology, Frankfurt Höchst Hospital and 
University Hospital, Heidelberg; M Reinhard and WD Niessen, Department of Neurology, 
University Hospital, Freiburg 
Italy: A. Zini, Stroke Unit, Department of Neuroscience, Nuovo Ospedale Civile, AUSL 
Modena, V. Caso, Department of Neurology, Perugia; A. Pezzini, University Hospital Brescia 
R. Tanaka; Department of Neurology, Juntendo University Hospital, Tokyo. K. Kamiyama; 
Department of Neurosurgery, Nakamura Memorial Hospital, Hokkaido. Y. Watanabe; 
Department of Neurosurgery, Fukushima Red Cross Hospital, Fukushima. 
The Netherlands: P. Nederkoorn and S. Zinkstok Academic Medical Center, University of 
Amsterdam 
Norway: E. Berge and M. Jusofovic, Department of Internal Medicine, Oslo University 
Hospital; A. Tveiten, Department of Neurology, Sorlandet Sykehus, Kristiansand; H. Naess 
and L. Thomassen, Department of Neurology and Centre for Neurovascular Diseases, 
Haukeland University Hospital; Bergen 
Switzerland: A. Eskandari and P. Michel, Department of Neurology, University Hospital 
Lausanne ;R. Stzajzel, Department of Neurology, University Hospital of Geneva and Medical 
School, Geneva; S. Wegener and A. Luft, Department of Neurology, University of Zurich; G. 
Kaegi, Department of Neurology, Kantonsspital St. Gallen; C. Traenka, H. Gensicke, GM De 
Marchis, L. Hert, L.H.. Bonati, N. Peters, P.A. Lyrer, D. Seiffge and S.T. Engelter, Stroke 
Center and Neurology, University Hospital Basel; Ch. Stippich and A. von Hessling, 
Department of Neuroradiology, University Hospital Basel 
Serbia: V. Padjen School of Medicine, University of Belgrade 
UK: A. Charidimou and D. J. Werring, Stroke Research Group, Department of Brain Repair 
and Rehabilitation, UCL Institute of Neurology and The National Hospital for Neurology and 
Neurosurgery, Queen Square, London 
 
*countries in alphabetic order 
 
  
Supplemental Table 1. Participating centers, number of contributed patients receiving acute 
recanalization therapies and data source. 
Center Recanalization 
therapies in 
patents on NOAC 
Recanalization 
therapies in 
patients on VKA 
Recanalization 
therapies in 
patients without 
anticoagulation 
Data source 
(registry or 
patient list*) 
Belgium     
University Hospital 
Brussels 
7 0 95 registry 
France     
University Hospital, 
Dijon,  
5 19 357 registry 
Lille University 
Hospital 
3 39 795 registry 
Sainte-Anne 
Hospital, Paris 
4 7 0 registry 
Finland     
University Central 
Hospital, Helsinki 
2 127 2482 registry 
Germany     
Charité University 
Hospital Berlin,  
11 34 877 registry 
University Hospital 
Frankfurt 
1 3 0 list 
Frankfurt Höchst 
Hospital 
3 0 0 list 
University Hospital 
Freiburg 
7 0 0 list 
Municipal Hospital 
Ludwigshafen 
0 8 136 registry 
Italy     
University Hospital 
Modena 
1 19 458 registry 
University Hospital 
Perugia 
1 0 0 registry 
University Hospital 
Brescia 
0 9 148 registry 
Japan 
Tokyo Women’s 
Medical University 
Hospital 
10 0 0 registry 
Netherlands     
Academic Medical 
Center, University of 
Amsterdam 
0 7 585 registry 
Norway     
Haukeland 
University Hospital 
2 5 224 registry 
Sorlandet Sykehus 
Kristiansand 
1 0 404 registry 
University Hospital 
Oslo 
0 7 3 registry 
Serbia     
University Hospital 
Belgrad 
0 7 322 registry 
Switzerland     
Centre Hospitalier 
Vaudois, Lausanne 
2 80 781 registry 
University Hospital 
Basel 
14 56 899 registry 
University Hospital 
Zürich# 
1 3 46 registry 
University Hospital, 
Geneva 
1 0 0 registry 
Kantonspital St. 
Gallen,  
0 15 322 registry 
United Kingdom 
University College 
London Hospitals 
NHS Foundation 
Trust London 
2 0 0 list 
Total 78 441 8938  
 
*Definition: 
“Registry”: In-hospital thrombolysis registry or stroke-registry of all consecutive patients receiving 
IVT/IAT with prospective ascertainment of all relevant data (at least vast majority).   
“List”: Lists of all consecutive stroke patients receiving IVT/IAT. Several individual patient data were 
derived from charts and/or records 
 
# recruitment period 04/2012-12/2013 
 
